Abstract: A cap assembly for a container, including a base having a handle and configured to be removably coupled to the container, a drink spout extending away from the base, a closure configured to selectively transition between a closed configuration, in which the closure is engaged with the drink spout and obstructs a passage through the drink spout, and an open configuration, in which the closure is not engaged with the drink spout and does not obstruct the passage through the drink spout, a tether coupling the closure to the base, a first portion of the tether extending around the drink spout and a second portion of the tether extending around the closure, and a magnetic closure retention mechanism configured to retain the closure in an open configuration.

Abstract: A hinge includes a hinge body, a self-close mechanism disposed within the hinge body, and a slow-close mechanism disposed within the hinge body. The hinge body has a first portion rotatable with respect to a second portion between an open position and a closed position. The self-close mechanism applies a closing force on the first portion from an opened angle of rotation between the first portion and the second portion to the closed position having a 0° angle of rotation between the first portion and the second portion. The closing force urges the first portion to the closed position. The slow-close mechanism applies a damping force on the first portion from the opened angle of rotation between the first portion and the second portion to the closed position. The damping force slows a rotational speed of the first portion to the closed position.

Abstract: Patients diagnosed with a cancer harboring an IDH-1 mutation can be treated by the administration of a therapeutically effective amount of a pharmaceutical composition comprising Compound 1, a selective inhibitor of 2-HG production from mIDH-1 enzymes including the R132 mutations R132C, R132H, R132L, R132G, and R132S.

Abstract: A hinge includes a hinge body, a self-close mechanism disposed within the hinge body, and a slow-close mechanism disposed within the hinge body. The hinge body has a first portion and a second portion, the first portion is rotatable with respect to the second portion between an open position and a closed position. The self-close mechanism applies a closing force on the first portion from a first angle of rotation between the first portion and the second portion to the closed position, the closing force urging the first portion to the closed position. The slow-close mechanism applies a damping force on the first portion from a second angle of rotation between the first portion and the second portion to the closed position, the damping force slowing a rotational speed of the first portion to the closed position.

Abstract: A junction box for electrical wiring includes a housing and a base plate. The housing is adapted to removably connect with the base plate to house the electrical connection. The base plate is secured to a support beam to provide stability to the junction box. The housing and the base plate are either of a unitary structure, or include tabs and/or attachment flanges that provide additional access and stability to the electrical connection, while reducing strain. The junction box may be secured to the support beam via a telescoping bar hanger.

Abstract: Patients diagnosed with a cancer harboring an IDH-1 mutation can be treated by the administration of a therapeutically effective amount of a pharmaceutical composition comprising Compound 1, a selective inhibitor of 2-HG production from mIDH-1 enzymes including the R132 mutations R132C, R132H, R132L, R132G, and R132S.

Abstract: A cap assembly for a container, including a base having a handle and configured to be removably coupled to the container, a drink spout extending away from the base, a closure configured to selectively transition between a closed configuration, in which the closure is engaged with the drink spout and obstructs a passage through the drink spout, and an open configuration, in which the closure is not engaged with the drink spout and does not obstruct the passage through the drink spout, a tether coupling the closure to the base, a first portion of the tether extending around the drink spout and a second portion of the tether extending around the closure, and a magnetic closure retention mechanism configured to retain the closure in an open configuration.

Abstract: A drink container include a liquid container having a neck with an opening and having an internal compartment sized to hold a volume of potable drink liquid and a cap assembly removably coupled to the liquid container, the cap assembly including a base removably coupled to the neck of the liquid container and including a through-passage extending through the base, a first catch structure coupled to the base, a mouthpiece assembly, a second catch structure adapted to selectively engage with the first catch structure and retain the mouthpiece assembly in the stowed configuration when engaged with the first catch structure, and a user release mechanism comprising an actuation surface, the user release mechanism being configured to disengage the first and second catch structures in response to a user pushing the actuation surface, to cause the mouthpiece assembly to move via its bias from the stowed configuration to the dispensing configuration.

Abstract: Patients diagnosed with a cancer harboring an IDH-1 mutation can be treated by the administration of a therapeutically effective amount of a pharmaceutical composition comprising Compound 1, a selective inhibitor of 2-HG production from mIDH-1 enzymes including the R132 mutations R132C, R132H, R132L, R132G, and R132S.

Abstract: A cap assembly for a container, including a base defining a base plane, a drink spout separate from the base and extending away from the base, a closure configured to selectively transition between a closed configuration, in which the closure is engaged with the drink spout and obstructs a passage through the drink spout, and an open configuration, in which the closure is not engaged with the drink spout and does not obstruct the passage through the drink spout, and a closure retention mechanism configured to retain the closure in any one of a plurality of stowed positions against the base.

Abstract: A drink container including a liquid container having a neck with an opening and having an internal compartment sized to hold a volume of potable drink liquid and a cap assembly removably coupled to the liquid container, the cap assembly including a base removably coupled to the neck of the liquid container and including a through-passage extending through the base, a first catch structure coupled to the base, a mouthpiece assembly including a rigid collar member, a mouthpiece portion extending from the rigid collar member, and second catch structure adapted to be selectively engaged with the first catch structure, and a user release mechanism adapted to automatically disengage the first and second catch structures upon actuation of the user release mechanism.

Abstract: Methods of treating patients diagnosed with AML or MDS harboring mutant IDH-1 include detecting an IDH1 mutation and the therapeutic administration of an inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA) or cytarabine.

Abstract: Patients diagnosed with a cancer harboring an IDH-1 mutation can be treated by the administration of a therapeutically effective amount of a pharmaceutical composition comprising Compound 1, a selective inhibitor of 2-HG production from mIDH-1 enzymes including the R132 mutations R132C, R132H, R132L, R132G, and R132S.

Abstract: Methods of treating patients diagnosed with cancer harboring an IDH-1 mutation are provided, including the therapeutic administration of a certain inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA).

Abstract: A closure assembly including a closure base configured to be selectively coupled to a neck of a liquid vessel and a valve assembly operatively coupled to the closure base, the valve assembly comprising a nozzle that extends away from the closure base and defines at least one drink outlet, shower outlets spaced around the at least one drink outlet, and a barrel valve, the barrel valve being configured to be selectively rotated relative to the closure base to transition the valve assembly between a closed configuration, in which a flow of liquid from the liquid vessel through the closure assembly is restricted, a drink configuration, in which liquid is permitted to flow from the liquid vessel through the drink outlet but not the shower outlets, and the shower configuration, in which liquid is permitted to flow from the liquid vessel through the shower outlets but not the drink outlet.

Abstract: A junction box for electrical wiring includes a housing and a base plate. The housing is adapted to removably connect with the base plate to house the electrical connection. The base plate is secured to a support beam to provide stability to the junction box. The housing and the base plate are either of a unitary structure, or include tabs and/or attachment flanges that provide additional access and stability to the electrical connection, while reducing strain. The junction box may be secured to the support beam via a telescoping bar hanger.

Abstract: Methods of treating patients diagnosed with AML or MDS harboring mutant IDH-1 include detecting an IDH1 mutation and the therapeutic administration of an inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA) or cytarabine.

Abstract: Methods of treating patients diagnosed with cancer harboring an IDH-1 mutation are provided, including the therapeutic administration of a certain inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA).

Abstract: Patients diagnosed with a cancer harboring an IDH-1 mutation can be treated by the administration of a therapeutically effective amount of a pharmaceutical composition comprising Compound 1, a selective inhibitor of 2-HG production from mIDH-1 enzymes including the R132 mutations R132C, R132H, R132L, R132G, and R132S.

Abstract: A cap assembly for a container, including a base defining a base plane, a drink spout separate from the base and extending away from the base, a closure configured to selectively transition between a closed configuration, in which the closure is engaged with the drink spout and obstructs a passage through the drink spout, and an open configuration, in which the closure is not engaged with the drink spout and does not obstruct the passage through the drink spout, and a closure retention mechanism configured to retain the closure in any one of a plurality of stowed positions against the base.